Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that primarily affects women in their reproductive years. Lupus occurred in 13,555 of 16.7 million pregnancies in a recent study in the United States.
We also reviewed the literature on new-onset SLE that manifested as preeclampsia during pregnancy and in the postpartum period, and discuss facilitation of rapid diagnosis.
Case Study
A 32-year-old primigravid Japanese woman with no remarkable medical history had become pregnant by in vitro fertilization and egg transfer. She underwent a prenatal checkup by a local doctor. Laboratory testing during the first trimester revealed anemia (hemoglobin level of 9.0 g/dL), thrombocytopenia (platelet count of 7.0 Â 10/µL), and proteinuria (2 þ ), but no further assessment was performed. When she was referred to a clinic near her parents' home at 29 weeks of gestation, leg edema, hypertension, intrauterine growth reduction (À2.3 standard deviation), and a high umbilical artery resistance index were observed. She was transferred to a city hospital and underwent further examination. On the same day, she was diagnosed with severe preeclampsia and a nonreassuring fetal status based on severe hypertension (160/100 mm Hg), thrombocytopenia (2.9 Â 10/µL), renal disorder (serum creatinine level of 1.25 mg/dL), and loss of variability on cardiotocography. She was transferred to our hospital immediately. An emergent cesarean section was performed under general anesthesia with preoperative transfusion of 10 units of concentrated platelets. A 1,048-g female infant was born with Apgar scores of 3 and 9 at 1 and 5 minutes, respectively. Although no major intraoperative problems occurred, awakening of the patient was delayed despite the cessation of anesthetic administration. She suddenly showed general convulsions in the operating room. An emergency computed tomographic examination of the head revealed no hemorrhage or infarction. We suspected eclampsia and began intravenous administration of magnesium sulfate, nicardipine hydrochloride, and unfractionated heparin. Magnetic resonance imaging the next day showed no occipital lobe lesions characteristic of posterior reversible encephalopathy syndrome. The general convulsions did not recur. Although her consciousness, hypertension, and serum creatinine levels had improved, her thrombocytopenia and anemia persisted. Therefore, frequent platelet transfusions were required (►Fig. 1). On postoperative day (POD) 3, we suspected an underlying autoimmune disorder, and a complete autoimmune workup was initiated. On POD4, we started intravenous prednisolone administration before diagnosis. Laboratory findings the following day showed positivity for antinuclear antibody, anti-ds DNA antibody, anti-Sm antibody, and anti-RNP antibody (72.5, 21, 170, and 109 IU/mL, respectively), and low C3 and C4 complement levels (42 and 8 mg/dL, respectively). Antiphospholipid antibodies, anti-Ro, and anti-La antibodies, antineutrophil cytoplasmic antibodies, antiplatelet factor 4/heparin antibodies, broken erythrocytes, and a disintegrin-like and metalloproteinase with thrombospondin type 1 motif 13 were negative. Plateletassociated IgG was almost normal (43.8 ng/10 7 cells). Based on these findings, she was diagnosed with SLE on POD5. Several days later, her platelet count and hemoglobin level increased to the reference ranges. Her proteinuria improved from 4 g/d on POD4 to 1 g/d on POD18, and her blood pressure normalized on POD7. The patient was discharged on POD34 with normal blood pressure, normal laboratory data, and no recurrence of seizures. Her SLE has been well controlled with oral prednisone. Evaluation of her newborn showed no evidence of neonatal lupus.
Discussion
SLE predominantly affects young women of child-bearing age.
There have been numerous studies of pregnant women diagnosed with SLE before conception, and the course of pregnancy with SLE has dramatically improved in recent decades. The average probability of a lupus flare during pregnancy and the postpartum period has decreased from 60.0% in the presteroid era to 23.3% at the beginning of the 21st century. 6 There is no consensus on whether the incidence of lupus flare increases during pregnancy and the postpartum period or in which trimester it is most associated with a risk of lupus flare. However, SLE activity during the 6 months preceding conception and preexisting renal disease are known as potential risk factors for flares during pregnancy. There is a greater prevalence of preeclampsia, fetal loss, intrauterine growth retardation, and preterm birth among women with active lupus during pregnancy. However, there are few reports on SLE during pregnancy and in the postpartum period. A literature search of MEDLINE and Japana Centra Revuo Medicina for reports published during the past 20 years showed only 13 case reports involving 16 patients, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] one comparative study on newonset SLE during pregnancy and the postpartum period, 21 and two studies that presented limited information.
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Among all 17 reported patients (16 previous reports plus the present case) (►Table 1), the mean maternal age was 28 years (range, 20-34 years). Excluding two cases in which such information was not provided; two cases involved abortion, nine involved preterm delivery, and only four involved term delivery. No cases of stillbirth or neonatal death were reported. Preeclampsia/eclampsia was the most common complication and was found in 11 (65%) cases. Hemophagocytic syndrome, acute fatty liver, HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome, and myocardial infarction were the other severe complications, but no maternal death was reported. The numbers of patients who manifested specific diagnostic criteria of SLE included the following: malar rash in 7 (41%); discoid rash in 2 (12%); photosensitivity in 0 (0%); oral ulcers in 3 (18%); arthritis in 4 (24%); serositis in 4 (24%); renal disorder in 11 (65%); neurological disorders in 3 (18%); leukopenia in 7 (41%); anemia in 6 (35%); thrombocytopenia in 6 (35%); anti-ds DNA in 14 (82%); and antinuclear antibody in 17 (100%). Renal disorders appeared to be more common at the onset of SLE in pregnant patients than in nonpregnant patients.
Zhao Of the 11 patients who developed preeclampsia/eclampsia in the above-described case reports, 3 developed preeclampsia after the diagnosis of SLE and 8 had SLE that manifested as preeclampsia that had not been initially diagnosed. In these eight patients, preeclampsia mostly occurred in the third trimester, with the exception of one patient who developed preeclampsia immediately after delivery. Of these seven patients, three developed preeclampsia as the first manifestation of SLE. The remaining four patients (including our patient) developed preeclampsia with preceding symptoms of SLE, such as leg edema, proteinuria, mild anemia, and thrombocytopenia, which are also commonly found in patients with preeclampsia, or even in patients with a normal pregnancy. No patients developed other typical symptoms of SLE (e.g., malar rash or arthritis) as the first manifestation of SLE in the third trimester or preceding preeclampsia before the diagnosis of SLE. These findings suggest that distinguishing underlying SLE from preeclampsia is difficult, especially in the third trimester, because other typical symptoms of SLE are not initially observed. Moreover, preeclampsia is common not only in patients with SLE, but also in healthy women in their third trimester of pregnancy. In six of the seven abovementioned patients, the pregnancy was terminated to treat the preeclampsia before the diagnosis of SLE, and all patients had a preterm delivery.
The diagnosis of SLE tended to be delayed (5 days to > 12 months after delivery) in the eight cases that manifested as preeclampsia because termination of pregnancy was believed to be sufficient to improve the condition, and an immunological examination was not initially performed. An autoimmune disorder was finally suspected when the condition worsened, even after parturition. Important factors for identifying underlying SLE were the persistence or new onset of the following abnormal physical or laboratory findings: malar rash, fever, purpuric macules on the fingers, acute heart failure, serositis, renal disorder, cytopenia, and recurrence of seizures.
In our case, the anemia, thrombocytopenia, and proteinuria that were incidentally found in the first trimester led us to the correct diagnosis. The persistence of thrombocytopenia and worsening anemia helped us to suspect an underlying autoimmune disease. When the platelet count does not reach its nadir for 48 to 72 hours, preeclampsia syndrome may be incorrectly attributed to a thrombotic microangiopathy. Thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, HELLP syndrome, acute fatty liver, or catastrophic antiphospholipid syndrome, all of which were ruled out by biochemical and immunological examinations, were considered to be the differential diagnoses.
In conclusion, new-onset SLE during pregnancy is rare and difficult to quickly diagnose, especially in cases that manifest as preeclampsia in the third trimester. New-onset SLE should be suspected and an autoimmune workup should be performed as soon as possible when symptoms of preeclampsia persist or new atypical symptoms of preeclampsia develop after delivery. 
